已收盤 11-20 16:00:00 美东时间
-0.970
-19.06%
On 20 Nov 2026, Strategy Inc (NasdaqGS:MSTR) saw its preferred stock STRC trade below the key US$100 level. The company kept STRC’s dividend at 12%, an unusually high yield for a preferred security at that price point. Management is using proceeds from new common equity issuance to repurchase STRC shares in the open market. The drop in STRC below US$100 and the 12% payout are important, but they should sit alongside other factors in any view on S
11-21 10:09
Strategy Inc. (NASDAQ:MSTR) has spent roughly $3 billion buying back its STRC preferred stock, and Executive Chairman Michael Saylor says there’s still billions more in demand left to tap. Saylor Sees Up To $7.5 Billion In Natural Demand "I don’t know exactly where the number is, but I’m going to go...
11-20 19:54
Pfizer invests $330 million in three pre-IND CAR-T programs targeting autoimmune diseases, reflecting industry interest in engineered T-cell therapies. SRX Global highlights its pending acquisition of CERo Therapeutics, developer of CER-1236, a clinical-stage T-cell therapy for hematologic malignancies. CER-1236, based on CERo's CER-T platform, is being tested in the Phase 1/1b CERTAIN-T trial, with seven patients dosed and no dose-limiting toxic...
11-20 17:58
Phunware's Board recommends re-electing Chairperson Elliot Han, highlighting his role in securing $104M capital, resolving liquidity, and advancing the 2.0 Strategy. Goldenwise's nominee, Xuan Zhang, lacks relevant experience and ties to Phunware's industry. Han's expertise in finance, governance, and technology aligns with the company's needs. Phunware urges shareholders to vote "FOR" Han on the WHITE proxy card, emphasizing continuity and strat...
11-20 13:31
Strategy Inc.’s (NASDAQ:MSTR) Stretch (NASDAQ:STRC) saw more than $600 million in trading volume this week, and Executive Chairman Michael Saylor says he’s not done buying. Strategy Spent Nearly Seven Times More on STRC Than Bitcoin "We intend to keep buying below $100," Saylor noted, adding that ST...
11-20 02:37
Gaming and Leisure Properties, Inc. (GLPI) announced the pricing of a $600 million public offering of senior notes due 2031, priced at 99.486% of par with a 6.250% coupon. The net proceeds will be used for working capital, general corporate purposes, and funding existing and new development commitments. The offering is expected to close on December 1, 2026, subject to closing conditions. The notes are senior unsecured obligations of the issuers, ...
11-19 23:12
Beacon Financial Corporation announced the appointments of Sumant Pustake as Chief Operating Officer and Peter R. Bakkala as Chief Internal Audit Officer. Pustake, with nearly 20 years of banking experience, will lead strategic priorities, digital strategy, and client experience. Bakkala, with over 40 years in banking, will oversee internal audit and SOX testing programs. Both appointments aim to strengthen the company's leadership and operationa...
11-19 21:05
Magna received two 2026 Automotive News PACE Innovation Partnership Awards for its collaborations with BMW on the EV Battery Enclosure with OptiForm™ Endcaps and with Jetour on the DHD Duo Hybrid Drive system, both in production. Additionally, its EcoSphere™ Bio-Based Foam was named a 2026 PACE Pilot Innovation to Watch. These recognitions highlight Magna's innovation capabilities in vehicle systems, addressing key industry challenges with scalab...
11-19 18:50
SEALSQ Corp在法国戛纳举办的SEALSQ Quantum Days活动中展示了其Quantum Sovereign Vertical Stack,强调了其“Root-to-Qubit-to-Space”架构,旨在提供量子安全解决方案。CEO Carlos Moreira在开幕致辞中讨论了硬件信任的重要性。活动亮点包括QS7001芯片的进展、与Eco Wave Power和SEALCOIN的合作演示,以及在量子计算和空间通信方面的投资。讨论主题涵盖后量子密码学、能源交易和量子安全芯片设计。此外,SEALSQ宣布了与QuintessenceLabs的收购意向,并在ASIC设计和卫星安全方面取得进展。
11-19 15:02
Evaxion A/S has refocused its strategy to prioritize immuno-oncology assets, leveraging its AI-Immunology™ platform for novel cancer target discovery and vaccine development. Key initiatives include advancing off-the-shelf vaccines EVX-04 and EVX-05, expanding EVX-01’s potential via partnerships, and identifying new targets from the dark genome. Recent highlights include presenting EVX-01’s three-year clinical data, winning the Prix Galien Award,...
11-19 12:00